Insights
Search Results
Client Highlights
4.09.26
Wilson Sonsini Advises Forte Biosciences on $150 Million Public Offering
On April 8, 2026, Forte Biosciences, Inc., a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, announced the pricing of a public offering of 5,709,936 shares of its common stock at a price to the public of $26.27 per share. The gross proceeds from the offering are expected to be approximately $150 million before deducting underwriting discounts and commissions and other offering expenses. Wilson Sonsini Goodrich & Rosati advised Forte Biosciences on the transaction.
Client Highlights
10.28.25
Wilson Sonsini Advises Avidity Biosciences on IP Matters Related to $12 Billion Acquisition by Novartis
On October 26, 2025, Novartis announced that it has entered into an agreement to acquire Avidity Biosciences, a San Diego-based biopharmaceutical company focused on a new class of therapeutics enabling RNA delivery to muscle. The acquisition will follow the separation of Avidity’s early-stage precision cardiology programs. Wilson Sonsini Goodrich & Rosati advised Avidity Biosciences on patent matters related to the transaction.
Client Highlights
9.12.25
Wilson Sonsini Advises Avidity Biosciences on Patent Matters Related to $600 Million Upsized Public Offering
On September 12, 2025, Avidity Biosciences, Inc., a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), announced the pricing of its upsized underwritten public offering of 15,000,000 shares of its common stock at a price to the public of $40.00 per share. All of the shares to be sold in the offering are to be sold by Avidity. The gross proceeds to Avidity from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be $600 million. Wilson Sonsini Goodrich & Rosati is advising Avidity Biosciences on patent matters related to the transaction.
Client Highlights
6.25.25
Firm Advises Forte Biosciences on $75 Million Public Offering
On June 24, 2025, Forte Biosciences, Inc., a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, announced the pricing of a public offering of shares of its common stock and pre-funded warrants at a price to the public of $12.00 per share. Wilson Sonsini Goodrich & Rosati advised Forte on the transaction. The gross proceeds from the offering are expected to be approximately $75 million before deducting underwriting discounts and commissions and other offering expenses. The offering is expected to close on or about June 26, 2025, subject to satisfaction of customary closing conditions.
Client Highlights
5.20.25
Firm Advises Sirius on Patent Matters Related to CRISPR Therapeutics Collaboration
On May 20, 2025, CRISPR Therapeutics, a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, and Sirius Therapeutics, a clinical-stage biotech company developing innovative small interfering RNA (siRNA) therapies for global markets, announced a strategic partnership to develop and commercialize novel siRNA therapies. Wilson Sonsini Goodrich & Rosati advised Sirius on patent matters related to the transaction.
Under the terms of the agreement, CRISPR Therapeutics will make an upfront payment of $25 million in cash and $70 million in equity to Sirius. The companies will jointly develop SRSD107—a next-generation, long-acting Factor XI (FXI) siRNA for the treatment of thromboembolic disorders—under a 50-50 cost and profit-sharing structure. CRISPR Therapeutics will lead commercialization in the U.S., while Sirius will be responsible for commercialization in Greater China. Additionally, CRISPR Therapeutics will have the option to nominate up to two siRNA targets for research and development. For each target, CRISPR Therapeutics will fund research and retain opt-in rights to lead clinical development and commercialization. Sirius will be eligible to receive milestone payments, as well as tiered royalties ranging from high-single to low-double digits.
The Wilson Sonsini team that advised Sirius on patent matters related to the transaction was led by Minyoung Shin and included Mike Hostetler, Hee Min Noh, Jen Zeng, and Tiara Wong.
For more information, please see the companies’ news release. Additional coverage is available in Fierce Biotech and BioSpace.
Under the terms of the agreement, CRISPR Therapeutics will make an upfront payment of $25 million in cash and $70 million in equity to Sirius. The companies will jointly develop SRSD107—a next-generation, long-acting Factor XI (FXI) siRNA for the treatment of thromboembolic disorders—under a 50-50 cost and profit-sharing structure. CRISPR Therapeutics will lead commercialization in the U.S., while Sirius will be responsible for commercialization in Greater China. Additionally, CRISPR Therapeutics will have the option to nominate up to two siRNA targets for research and development. For each target, CRISPR Therapeutics will fund research and retain opt-in rights to lead clinical development and commercialization. Sirius will be eligible to receive milestone payments, as well as tiered royalties ranging from high-single to low-double digits.
The Wilson Sonsini team that advised Sirius on patent matters related to the transaction was led by Minyoung Shin and included Mike Hostetler, Hee Min Noh, Jen Zeng, and Tiara Wong.
For more information, please see the companies’ news release. Additional coverage is available in Fierce Biotech and BioSpace.
Client Highlights
5.12.25
Firm Advises HAYA Therapeutics on Patent Matters Related to $65 Million Series A Financing
On May 8, 2025, HAYA Therapeutics, a biotechnology company pioneering precision RNA-guided regulatory genome targeting therapeutics that reprogram disease-driving cell states for rare, common, chronic and age-related diseases, announced that the company has raised $65 million in Series A funding. The round was led by Sofinnova Partners and Earlybird Venture Capital, with participation from Eli Lilly, ATHOS, +ND Capital, Alexandria Venture Investments, and LifeLink Ventures, with additional support from existing investors. Wilson Sonsini Goodrich & Rosati advised HAYA Therapeutics on patent matters related to the transaction.
Client Highlights
5.12.25
Firm Advises Sirius Therapeutics on Patent Matters Related to $50 Million Series B2 Financing
On May 9, 2025, biotechnology company Sirius Therapeutics announced that it has successfully completed nearly $50 million Series B2 financing. A corporate venture capital firm led the financing round and was joined by new investor BioTrack Capital and existing investors OrbiMed, Creacion Ventures, and Hankang Capital. Wilson Sonsini Goodrich & Rosati advised Sirius Therapeutics on patent matters related to the transaction.
Client Highlights
4.15.25
Wilson Sonsini Advises Oak Hill Bio on Patent Matters Related to Exclusive License Agreement with Roche
On April 15, 2025, Oak Hill Bio, a biotechnology company focused on acquiring and developing life-changing rare disease therapeutics, entered into an exclusive license agreement with Roche to obtain global rights for rugonersen (RO7248824). Rugonersen is an ASO designed as a potential best-in-class treatment for individuals with Angelman syndrome, a rare, genetic neurodevelopmental condition for which there is no approved disease-modifying treatment. Wilson Sonsini Goodrich & Rosati advised Oak Hill Bio on patent matters related to the transaction.
Client Highlights
1.09.25
Wilson Sonsini Advises General Atlantic on IP Matters Related to Verdiva Bio’s Formation and $410 Million Series A
On January 9, 2025, Verdiva Bio Limited announced its launch as a clinical-stage biopharmaceutical company focused on developing innovative therapies for obesity and other cardiometabolic disorders. Verdiva launched with an oversubscribed Series A financing of $411 million, co-led by General Atlantic and Forbion, with additional participation from RA Capital Management, OrbiMed, Logos Capital, Lilly Asia Ventures, and LYFE Capital (collectively, “the Investor Group”). Wilson Sonsini Goodrich & Rosati advised General Atlantic on IP matters related to Verdiva’s formation and Series A funding round.
Verdiva is advancing a portfolio of next-generation oral and injectable treatments with first-in-class or best-in-class potential. The company is committed to developing next-generation therapies to help people living with obesity, cardiometabolic disorders, and related complications achieve better outcomes via more patient-friendly therapeutic options. Verdiva’s most advanced therapy is VRB-101, an oral GLP-1 peptide in clinical development that has demonstrated best-in-class efficacy potential in a phase 1 study in Australia.
Verdiva is advancing a portfolio of next-generation oral and injectable treatments with first-in-class or best-in-class potential. The company is committed to developing next-generation therapies to help people living with obesity, cardiometabolic disorders, and related complications achieve better outcomes via more patient-friendly therapeutic options. Verdiva’s most advanced therapy is VRB-101, an oral GLP-1 peptide in clinical development that has demonstrated best-in-class efficacy potential in a phase 1 study in Australia.
Client Highlights
11.21.24
Wilson Sonsini Advises Forte Biosciences on Oversubscribed $53 Million Equity Financing
On November 20, 2024, biopharmaceutical company Forte Biosciences announced an oversubscribed $53 million equity financing to support the continuing clinical advancement of FB102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. TD Cowen acted as the lead placement agent for the financing. Guggenheim Securities provided Capital Markets Advisory services to Forte Biosciences. Chardan, Rodman & Renshaw and Brookline Capital Markets acted as co-placement managers for the financing.
Client Highlights
10.23.24
Wilson Sonsini Advises General Atlantic on Patent Matters Related to Seaport Therapeutics' Oversubscribed $225 Million Series B
On October 21, 2024, Seaport Therapeutics, a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines, announced the completion of an oversubscribed $225 million Series B financing round. The funding was led by General Atlantic, a leading global growth investor, with participation from funds and accounts advised by T. Rowe Price Associates, Foresite Capital, Invus, Goldman Sachs Alternatives, CPP Investments, and other new investors. Founding investors ARCH Venture Partners, Sofinnova Investments, Third Rock Ventures, and co-founder PureTech Health also participated. Wilson Sonsini Goodrich & Rosati advised General Atlantic on patent matters related to the transaction.
Client Highlights
9.05.24
Wilson Sonsini Advises HAYA Therapeutics on Patent Matters Related to Collaboration with Eli Lilly
On September 4, 2024, HAYA Therapeutics, a biotechnology company pioneering precision RNA-guided regulatory genome targeting therapeutics for chronic diseases, announced a multi-year agreement with Eli Lilly and Company to apply HAYA’s advanced RNA-guided regulatory genome platform to support preclinical drug discovery efforts in obesity and related metabolic conditions. Wilson Sonsini Goodrich & Rosati advised HAYA on patent matters related to the transaction.